The polymorphisms RAD51/G135C, ATM/P1054R, and CHEK2/T470C were selected because they were associated with many cancers, such as prostate, breast, head and neck cancer, and leukemias (Skasko et al. 2009; Schumacher et al. 2018; Zeng et al. 2018). Here, CHEK2 is linked to cancer.